Introduction: To study efficacy and side effects of Tibolone in alleviating postmenopausal symptoms and compare it with vaginal estrogen.
Materials and methods: This prospective study was done on 100 postmenopausal women with amenorrhea of more than 1 year. All patients had one or more urogenital complaints. They were randomly assigned to receive Tibolone tablet 2.5 mg once daily (50 cases; group I) and vaginal estrogen (50 cases; group II). Both groups were compared at 1 and 6 months after starting treatment for genitourinary complaints. Chi-square test was used for comparison. A p-value of 0.05 was considered as significant.
Results: After 1 month of t/t, Tibolone was slightly better in relieving genital symptoms, while significantly improved dyspareunia and dryness in vagina after 6 months as compared with estrogen. After 6 months both groups showed clinically marked improvement in dysuria, frequency, and urgency.
Conclusion: Tibolone was better than estrogen in relieving dyspareunia and dryness in vagina. Both are equally effective in relieving urogenital symptoms, decreasing the recurrence rate of vaginal and urinary infections, and bringing out improvement in general well-being. Tibolone causes less nausea, edema, breakthrough bleeding as compared with estrogen.
Keywords: Dyspareunia, Estrogen, Tibolone, Urogenital symptoms, Vaginal dryness.
How to cite this article: Agarwal R, Agrawal M, Singh R, Mittal V, Rani R, Garg R. Tibolone: An Emerging Option as Hormone Replacement Therapy and Its Comparison with Vaginal Estrogen in Relieving Urogenital Symptoms. J South Asian Feder Menopause Soc 2016;4(2):69-74.
Source of support: Nil.
Conflict of interest: None.
Date of submission: 12 March 2016
Date of acceptance: 15 May 2016
Date of publication: July 2016